Epizyme, Inc. (EPZM) financial statements (2020 and earlier)

Company profile

Business Address 400 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:381240276242208190124
Cash and cash equivalents1398722778208190124
Short-term investments24215450164   
Other undisclosed cash, cash equivalents, and short-term investments0(0)(0)0   
Receivables320000234
Other undisclosed current assets161296432
Total current assets:399273286249213195160
Noncurrent Assets
Operating lease, right-of-use asset21
Property, plant and equipment2233442
Other noncurrent assets2111111
Total noncurrent assets:25344543
TOTAL ASSETS:425276289252218199163
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities31242521161814
Accounts payable9575585
Accrued liabilities232018161177
Employee-related liabilities     33
Debt30011  
Deferred revenue and credits  2223
Contract with customer, liability13
Other liabilities000    
Other undisclosed current liabilities     (3)(3)
Total current liabilities:34382522181735
Noncurrent Liabilities
Long-term debt and lease obligation190 01  
Capital lease obligations0 01  
Operating lease, liability19
Liabilities, other than long-term debt452929292224
Deferred revenue and credits2929292124
Deferred revenue4
Contract with customer, liability4
Other liabilities0110000
Total noncurrent liabilities:2352929302224
Total liabilities:57425451483959
Stockholders' equity
Stockholders' equity attributable to parent331233235202170160104
Preferred stock37      
Common stock0000000
Additional paid in capital1,051820724555413271160
Accumulated other comprehensive income (loss)0(0)(0)(0)   
Accumulated deficit(757)(587)(488)(354)(243)(111)(56)
Total stockholders' equity:331233235202170160104
Other undisclosed liabilities and equity36      
TOTAL LIABILITIES AND EQUITY:425276289252218199163

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net10834168
Gross profit:242210834168
Operating expenses(201)(150)(147)(120)(135)(97)(72)
Other undisclosed operating income     11
Operating loss:(177)(128)(137)(112)(133)(55)(3)
Nonoperating income (expense)752200(0)
Other nonoperating income (expense)(0)(0)0000(0)
Loss from continuing operations before income taxes:(170)(124)(135)(110)(132)(55)(3)
Income tax expense (benefit)(0)(0)0  (0)(0)
Net loss attributable to parent:(170)(124)(134)(110)(132)(55)(3)
Preferred stock dividends and other adjustments      (0)
Other undisclosed net loss available to common stockholders, basic(3)      
Net loss available to common stockholders, diluted:(173)(124)(134)(110)(132)(55)(4)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(170)(124)(134)(110)(132)(55)(3)
Comprehensive loss:(170)(124)(134)(110)(132)(55)(3)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)0(0)   
Comprehensive loss, net of tax, attributable to parent:(170)(124)(134)(110)(132)(55)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: